Boston, MA 10/01/2013 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had launched the anti-obesity drug Belviq about three months back. It is the first drug, in a period of 13 years, to be permitted by the Food and Drug Administration for this purpose. In these three months, impressive results of the drug have been reported. Patients who are already being treated for obesity and are taking weight loss drugs have shown improved outcomes.
The way this new chemical entity influences weight loss in the body is a little different from what other drugs have been doing till date. Belviq plays on the brain rather than producing effects in the stomach of the individual. Instead of burning fats inside the body, it acts by curbing the desire for food in its patients. The results, as noted by a medical practitioner in Tucson, were far greater than satisfactory and his patients have reported loss of a good deal of weight.
The three month period is crucial for the drug to start producing results. If after a 12 weeks trial, no loss of weight is noticed, it is advisable to discontinue the usage of the drug. Ideally, in 12 weeks, a person should step down by around 5% of his initial body weight.
In the Biotech Industry Conference, Arena Pharmaceuticals presented a brief synopsis about the drug and put forth its plans of launching the drug in the global market. The company plans to instruct doctors and other medical professionals about the drug and its efficiency at the launch of the product. Alongside other marketing strategies, the company is also keen on offering a free trail of 15 days to introduce the drug to its potential consumers, in collaboration with Eisai Co. Ltd., a healthcare firm based out of Tokyo. Belviq is expected to surge up the figures in the balance sheet of the company.
